These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 36318979)

  • 21. Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks.
    Pai YW; Chen IC; Lin JF; Chen XH; Chen HH; Chang MH; Huang JA; Lin CH
    Diabetes Obes Metab; 2024 Nov; 26(11):5420-5430. PubMed ID: 39248211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM
    Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus.
    Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
    Diabet Med; 2022 Aug; 39(8):e14858. PubMed ID: 35460294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.
    Tsai HR; Lin YJ; Yeh JI; Huang YC; Liu PP; Peng CC; Hsu JY; Lee YC; Loh CH; Lin SM; Huang HK
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3739. PubMed ID: 37862117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
    Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
    Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.
    Zhuo M; Paik JM; Wexler DJ; Bonventre JV; Kim SC; Patorno E
    Am J Kidney Dis; 2022 Jun; 79(6):858-867.e1. PubMed ID: 34762974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
    Bidulka P; Lugo-Palacios DG; Carroll O; O'Neill S; Adler AI; Basu A; Silverwood RJ; Bartlett JW; Nitsch D; Charlton P; Briggs AH; Smeeth L; Douglas IJ; Khunti K; Grieve R
    BMJ; 2024 May; 385():e077097. PubMed ID: 38719492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
    Dave CV; Schneeweiss S; Kim D; Fralick M; Tong A; Patorno E
    Ann Intern Med; 2019 Aug; 171(4):248-256. PubMed ID: 31357213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
    Brunetti VC; St-Jean A; Dell'Aniello S; Fisher A; Yu OHY; Bugden SC; Daigle JM; Hu N; Alessi-Severini S; Shah BR; Ronksley PE; Lix LM; Ernst P; Filion KB;
    BMC Endocr Disord; 2022 Sep; 22(1):241. PubMed ID: 36175881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

  • 32. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
    Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Gallbladder and Bile Duct Disease Among Patients with Type 2 Diabetes: A Population-Based Cohort Study.
    Shapiro SB; Yin H; Yu OHY; Azoulay L
    Drug Saf; 2024 Aug; 47(8):759-769. PubMed ID: 38720114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes.
    Kutz A; Kim DH; Wexler DJ; Liu J; Schneeweiss S; Glynn RJ; Patorno E
    Diabetes Care; 2023 Nov; 46(11):2004-2014. PubMed ID: 37677118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.
    Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD
    Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.
    Simon TG; Patorno E; Schneeweiss S
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1382-1393.e19. PubMed ID: 34256144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
    Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
    JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy.
    Cesta CE; Rotem R; Bateman BT; Chodick G; Cohen JM; Furu K; Gissler M; Huybrechts KF; Kjerpeseth LJ; Leinonen MK; Pazzagli L; Zoega H; Seely EW; Patorno E; Hernández-Díaz S
    JAMA Intern Med; 2024 Feb; 184(2):144-152. PubMed ID: 38079178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
    JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.